In this episode of the Better Science Better Health podcast, Gwen and Petra take on another jargon-heavy stretch of the Vital Health Podcast with Steve Potts and Duane Schulthess and unpack what is really being said about biotech financing, drug development, and the policy rules shaping investment.

From Series A funding to seed money, clinical assets, INDs, NDAs, BLAs, follow-on studies, and the famous 9-versus-13-year debate, they slow the conversation down and translate the terminology into plain English.

Along the way, they explain why biotech companies need so much funding before a medicine ever reaches patients, why investors think differently about small-molecule drugs and biologics, and how policy choices like the IRA can affect whether companies pursue new uses for existing treatments. It is a practical look at how science, money, regulation, and incentives all come together in the long and risky process of getting new medicines from the lab to the people who need them.

View the full Vital Health Podcast episode “Steve Potts: Policy Headwinds Are Reshaping Biotech Financing” here: